Predicting success in phase III studies from phase II results: a new paradigm is needed
J Clin Oncol
.
2008 Jul 20;26(21):3653-4; author reply 3654-5.
doi: 10.1200/JCO.2008.17.5000.
Authors
Richard Leff
,
Michele Andrews
PMID:
18640948
DOI:
10.1200/JCO.2008.17.5000
No abstract available
Publication types
Comment
Letter
MeSH terms
Antineoplastic Agents / therapeutic use*
Clinical Trials, Phase II as Topic*
Clinical Trials, Phase III as Topic
Humans
Neoplasms / drug therapy*
Substances
Antineoplastic Agents